Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics

Myriad Genetics logoMyriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing, or assess a patient's risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MYGN
  • CUSIP: 62855J10
Key Metrics:
  • Previous Close: $20.71
  • 50 Day Moving Average: $27.67
  • 200 Day Moving Average: $33.17
  • Trailing P/E Ratio: 12.11
  • Foreward P/E Ratio: 16.70
  • P/E Growth: 3.40
  • Market Cap: $1.43B
  • Outstanding Shares: 69,134,000
  • Beta: 0.55
Additional Links:
Companies Related to Myriad Genetics:

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $31.92 (54.14% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
DateFirmActionRatingPrice TargetDetails
8/21/2016Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
8/11/2016Jefferies GroupLower Price TargetHold$34.00 -> $20.00View Rating Details
8/11/2016StephensSet Price TargetBuy$30.00View Rating Details
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 -> $21.00View Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00View Rating Details
8/10/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$47.00 -> $22.00View Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00View Rating Details
8/10/2016Barclays PLCDowngradeOverweight -> Equal Weight$50.00 -> $24.00View Rating Details
7/29/2016Bank of America Corp.DowngradeNeutral -> Underperform$25.00View Rating Details
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00View Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00View Rating Details
3/23/2016Goldman Sachs Group Inc.Boost Price Target$40.00View Rating Details
2/3/2016Deutsche Bank AGReiterated RatingBuy$52.00 -> $51.00View Rating Details
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details
9/20/2015William BlairReiterated RatingBuyView Rating Details
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00View Rating Details
5/28/2015Credit Suisse Group AGReiterated RatingUnderperformView Rating Details
5/7/2015Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details
2/4/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.32$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.48$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
Current Year EPS Consensus Estimate: $1.08 EPS
Next Year EPS Consensus Estimate: $1.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.37$0.38$0.38
Q2 20164$0.41$0.43$0.42
Q3 20161$0.42$0.42$0.42
Q4 20162$0.36$0.45$0.41
Q1 20173$0.25$0.42$0.31
Q2 20173$0.29$0.46$0.35
Q3 20173$0.27$0.43$0.32
Q4 20173$0.25$0.38$0.29
(Data provided by Zacks Investment Research)


Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline logoETF’s with exposure to Myriad Genetics, Inc. : August 29, 2016 (NASDAQ:MYGN) - August 29 at 6:09 PM logoShares of MYGN Down 39.7% Since Downtrend Call on Shares (NASDAQ:MYGN) - August 25 at 6:19 PM logoStocks in Focus: Myriad Genetics, Inc. (MYGN), Facebook, Inc. (FB), Colony Capital, Inc. (CLNY) - iStreetWire (NASDAQ:MYGN) - August 25 at 11:27 AM logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: 2016 By the Numbers : August 23, 2016 (NASDAQ:MYGN) - August 23 at 10:46 AM logoMYRIAD GENETICS INC Financials (NASDAQ:MYGN) - August 20 at 6:04 PM logoMYGN: Insiders vs. Shorts (NASDAQ:MYGN) - August 19 at 6:16 PM logoMyriad Genetics Has Returned 39.6% Since SmarTrend Recommendation (MYGN) (NASDAQ:MYGN) - August 19 at 9:24 AM logoWeakness Seen in Myriad Genetics (MYGN) Estimates: Should You Stay Away? (NASDAQ:MYGN) - August 19 at 9:24 AM
News IconIt's Earnings Time: What to Do with Myriad Genetics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MYGN) - August 18 at 6:29 PM logoAnalysts See Sales Of $1009.5 For Myriad Genetics, Inc. (NASDAQ:MYGN) - Investor Newswire (NASDAQ:MYGN) - August 18 at 9:25 AM logoEXCLUSIVE: Assurex Health buyer has a Cincinnati connection (NASDAQ:MYGN) - August 16 at 6:31 PM logoTrader Alert: Zoetis Inc. (ZTS), CenturyLink, Inc. (CTL), Myriad Genetics, Inc. (MYGN) - iStreetWire (NASDAQ:MYGN) - August 16 at 9:39 AM logoETF’s with exposure to Myriad Genetics, Inc. : August 15, 2016 (NASDAQ:MYGN) - August 15 at 6:33 PM logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q4, 2016 By the Numbers : August 12, 2016 (NASDAQ:MYGN) - August 12 at 6:26 PM logoMyriad Genetics Inc. (MYGN) Has Plunged To A New Low After Weak Q4 Report (NASDAQ:MYGN) - August 12 at 9:35 AM logoMyriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session (NASDAQ:MYGN) - August 12 at 9:35 AM logoMyriad Genetics Has Downside in Its DNA (NASDAQ:MYGN) - August 11 at 6:45 PM logoWill Myriad Genetics (MYGN) Stock React to Price Target Cut at Jefferies? (NASDAQ:MYGN) - August 11 at 6:45 PM logoWhy the value of Assurex Health's buyer just plummeted (NASDAQ:MYGN) - August 11 at 6:45 PM logoMyriad Genetics Shares Down 43.1% Since SmarTrend's Sell Call (MYGN) (NASDAQ:MYGN) - August 11 at 9:31 AM logoBuzz Stocks: Eli Lilly and Co, Myriad Genetics, Inc., and Perrigo Company plc (NASDAQ:MYGN) - August 11 at 9:31 AM logoNew 52 Week Lows, Afternoon Update – (NASDAQ: MYGN), (NYSE: TDW), (NASDAQ: MCHX), (NYSE: PRGO), (Toronto Stock Exchange: CRME) (NASDAQ:MYGN) - August 11 at 9:31 AM logoMyriad Genetics Inc. (MYGN) Plunged To A New Low After Q4 Miss (NASDAQ:MYGN) - August 11 at 9:31 AM
News IconBrokerage Recom. Worth Watching: Myriad Genetics, Inc. (NASDAQ:MYGN) - The Voice Registrar (NASDAQ:MYGN) - August 10 at 6:46 PM
News IconActive Volatile Stocks- BioMarin Pharmaceutical (NASDAQ:BMRN), Myriad Genetics (NASDAQ:MYGN), Biogen ... - Seneca Globe (NASDAQ:MYGN) - August 10 at 6:46 PM
News IconSunPower Corporation (NASDAQ:SPWR) & Myriad Genetics, Inc. (NASDAQ:MYGN) Movers to Watch - Money News (press release) (NASDAQ:MYGN) - August 10 at 6:46 PM logoMid-Afternoon Market Update: Dow Falls 50 Points; Myriad Genetics Shares Decline Following Downbeat Results (NASDAQ:MYGN) - August 10 at 3:57 PM logoWhy Myriad Genetics, Inc. Got Pummeled Today (NASDAQ:MYGN) - August 10 at 1:52 PM
News IconWhy Analysts Are Abandoning Myriad Genetics Upside Hopes (NASDAQ:MYGN) - August 10 at 11:01 AM logoMyriad Genetics shares drop more than 20% on outlook, earnings - MarketWatch (NASDAQ:MYGN) - August 10 at 9:27 AM logoEdited Transcript of MYGN earnings conference call or presentation 9-Aug-16 8:30pm GMT (NASDAQ:MYGN) - August 10 at 9:27 AM logo[$$] With Trio of Exits, Claremont Creek Finds Success in Diagnostics (NASDAQ:MYGN) - August 10 at 9:27 AM logoMyriad Genetics (MYGN) Lags Q4 Earnings, New Tests Shine (NASDAQ:MYGN) - August 10 at 9:27 AM logoMyriad Genetics stock set to open at 2 1/2-year low after downbeat earnings (NASDAQ:MYGN) - August 10 at 8:10 AM logoMyriad Genetics -21% after guiding FQ1, full-year 2017 below consensus (NASDAQ:MYGN) - August 9 at 6:40 PM logoMyriad Genetics Inc.: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results (NASDAQ:MYGN) - August 9 at 6:37 PM logoMyriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results (NASDAQ:MYGN) - August 9 at 6:37 PM logoMyriad Genetics shares drop more than 20% on outlook, earnings (NASDAQ:MYGN) - August 9 at 6:37 PM logoMyriad Genetics Inc. (MYGN) Is Falling After Q4 Miss (NASDAQ:MYGN) - August 9 at 6:37 PM logoMyriad misses Street 4Q forecasts (NASDAQ:MYGN) - August 9 at 6:36 PM logo[$$] Myriad Genetics Shares Fall Amid Dour Outlook (NASDAQ:MYGN) - August 9 at 6:36 PM logoMyriad Genetics Weak Guidance Drives Shares Down 20% (NASDAQ:MYGN) - August 9 at 6:21 PM logoQ4 2016 Myriad Genetics Inc Earnings Release - After Market Close (NASDAQ:MYGN) - August 9 at 9:31 AM logoSurprising Analyst 12-Month Target For FBT (NASDAQ:MYGN) - August 8 at 11:00 AM
News IconIt's Earnings Time: What to Do with Myriad Genetics, Inc. (NASDAQ:MYGN) Stock - The Voice Registrar (NASDAQ:MYGN) - August 6 at 6:27 PM logoStrong Sell Calls For Myriad Genetics, Inc. (NASDAQ:MYGN) At 2 - Investor Newswire (NASDAQ:MYGN) - August 6 at 6:27 PM
News IconTraders Recap on Worth Watching Stocks: Myriad Genetics, Inc. (NASDAQ:MYGN), Maiden Holdings, Ltd. (NASDAQ ... - NYSE Journal (press release) (NASDAQ:MYGN) - August 6 at 6:27 PM logoMyriad Genetics, Inc. (NASDAQ:MYGN): Updated Analyst Ratings - Review Fortune (NASDAQ:MYGN) - August 6 at 6:27 PM logoMyriad Genetics (MYGN) to Acquire Assurex Health in ~$410M Deal - (NASDAQ:MYGN) - August 5 at 9:26 AM logo[$$] Myriad Genetics to Acquire Assurex Health for $410M (NASDAQ:MYGN) - August 5 at 9:26 AM


Myriad Genetics (NASDAQ:MYGN) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff